This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
EYLEA General
nAMD
DMO

WELCOME TO CONFIDENCE, EXTENDED

EYLEA 8 mg is the first and only anti-VEGF in nAMD and DMO that allows for extensions up to Q20*, with a safety profile comparable to EYLEA 2 mg. So you can confidently extend treatment intervals to help optimise your clinic's capacity.1–5

 

nAMD

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).1

 

With EYLEA 8 mg you could optimise your patient’s treatment journey and your clinic’s capacity1–3

Save sight

whilst minimising treatment burden2,3

Extend treatment intervals

across your clinic as far as Q202,3*†

Suppress VEGF

with a safety profile comparable to EYLEA 2 mg1–3

With only 3 loading doses and as few as 8 injections over 2 years
1‡§

*Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q20 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.1  
†Extend treatment intervals across your nAMD clinic, as far as Q20, for your eligible nAMD patients.2,3  
‡Patients could receive as few as 8 injections per dosing schedule within the trial protocol.3  
§Loading doses refers to the initial monthly dosing phase.2

PULSAR

Optimise vision whilst minimising burden

Primary endpoint: mean change in BCVA from baseline to Week 48

With EYLEA 8 mg, patients achieved lasting BCVA gains from baseline with as few as 5 injections in Year 12*

  • EYLEA 8 mg was non-inferior vs. EYLEA 2 mg2

*Includes 3 initial monthly doses.1

  • Extend treatment intervals for eligible patients across your nAMD clinic

    In PULSAR, ~8 out of 10 patients maintained 16-week treatment intervals from baseline through Week 482*

    PULSAR treatment intervals week 48

    *Patients completing Week 48: 2Q8 n=309; 8Q12 n=316; 8Q16 n=312.2

  • Extend treatment intervals for eligible patients across your nAMD clinic

    In PULSAR, ~8 out of 10 patients achieved a last assigned dosing interval of ≥Q16 at Week 963*

    PULSAR treatment intervals week 96 updated

    *Patients completing Week 96: 8Q12 n=291; 8Q16 n=292.3

     

    Extend treatment intervals beyond expectations 

    The first and only anti-VEGF for nAMD that allows for extension to treatment intervals of Q20 after reaching Q161*

    PULSAR treatment intervals week 96-2 updated

    *Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q20 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.1
    †Patients completing Week 96: 8Q12 n=291; 8Q16 n=292.3

See how you could optimise your DMO patient's treatment journey and your clinic's capacity with EYLEA 8 mg
Dosing

Discover proactive dosing in nAMD and DMO

MoA

Discover more about the MoA of EYLEA 8 mg

nAMD Safety Profile

Explore the safety profile of EYLEA 8 mg in nAMD

Abbreviations

2Q8, 2 mg every 8 weeks. 8Q12, 8 mg every 12 weeks. 8Q16, 8 mg every 16 weeks. BCVA, best-corrected visual acuity. CI, confidence interval. CRT, central retinal thickness. CST, central subfield thickness. DMO, diabetic macular oedema. DRM, dose regimen modification. ETDRS, Early Treatment of Diabetic Retinopathy Study. FAS, full analysis set. ICE, intercurrent event. IRF, intraretinal fluid. LOCF, last observation carried forward. LS, least squares. MMRM, mixed model for repeated measurements. MoA, mechanism of action. nAMD, neovascular (wet) age-related macular degeneration. Q8, every 8 weeks. Q16, every 16 weeks. Q20, every 20 weeks. SD, standard deviation. SmPC, Summary of Product Characteristics. SRF, subretinal fluid. T&E, treat and extend. VEGF, vascular endothelial growth factor.

References

  1. EYLEA® 114.3 mg/mL Summary of Product Characteristics.
  2. Korobelnik J-F. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR trial. Retina Society. 2–5 November 2022. Pasadena, USA. Oral presentation.
  3. Lanzetta P, et al. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 60-week and 96-week results from the Phase 3 PULSAR trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
  4. Brown DM. Aflibercept 8 mg in patients with nAMD: 48-week results from the phase 3 PULSAR trial. Angiogenesis, exudation, and degeneration 2023. 10–11 February 2023. Virtual. Oral presentation.
  5. ClinicalTrials.gov. NCT04423718. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT04423718. Accessed: August 2024.

PP-EYL-GB-2322 | August 2024

Next Page
Safety Profile